Premalignant variations in extracellular matrix composition in chemically induced hepatocellular carcinoma in rats.
Chemical composition of extracellular matrix (ECM) plays a pivotal role in cellular and tissue development, regeneration, and differentiation. It also plays a key role in pathogenesis of hepatocellular carcinoma (HCC). This study explored premalignant changes in the liver tissue content of collagen (as hydroxyproline, HP), total glycosaminoglycans (TGAGs), free glucosamine (FGA), total sialic acid (TSA), lysosomal membrane integrity variations (calculated as total and free cathepsin D activities), and liver histology. Serum alfa-fetoprotein (AFP) level was used as an early marker for HCC in two groups of Wistar rats. One group of rats served as control and was provided normal saline orally. The other group was provided trichloroacetic acid (TCA) as 0.5 g/kg/day for five consecutive days by oral gavage. Animals were killed before tumor development. The treatment revealed dysplastic changes in addition to microsteatosis (fatty changes). Both sinusoids and the portal vein among dysplastic cells were dilated and congested. These dysplastic foci are believed to be premalignant and may be precancerous lesions. The following things were observed: a highly significant increase in serum AFP (as a key marker for HCC), a significant decrease in HP and TSA, a significant increase in FGA, nonsignificant decrease in TGAGs, significant up-regulation of free cathepsin D, nonsignificant decrease in total cathepsin D activities, and destabilization of lysosomal membrane integrity. Down-regulation of HP, TSA, and TGAGs seems to be a prerequisite for cancer development. This might be stimulated by up-regulation of free cathepsin D activity. Perhaps tissue fibrosis is not a condition for developing HCC because collagen was significantly depressed. Up-regulated FGA could be assumed to be a defense mechanism against TCA-induced proteolysis of membrane proteins because it is frequently reported to be of value in cancer chemotherapy. Studied ECM perturbations can be assumed as preliminary changes during chemical hepatocarcinogenesis at the tissue level. Prospective studies on blood levels of cathepsins, TGAGs, and individual ECM variables such as TSA, FGA, and Hp in patients at risk for HCC, performed in parallel with assessments of AFP, may provide a cost-effective way to find new links between tissue changes and circulation that would permit early prediction of disease. It may also provide a way to monitor HCC and compensate for the missed peak AFP values.
Abdel-Hamid
Nabil M
NM
Department of Biochemistry, College of Pharmacy, Minia University, Minia, Egypt. nabilmohie@yahoo.com
D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000378:metabolism*; D002402:Cathepsin D; D004797:Enzyme-Linked Immunosorbent Assay; D005109:Extracellular Matrix / Q000737:chemistry* / Q000378:metabolism*; D005944:Glucosamine / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism; D006909:Hydroxyproline / Q000378:metabolism; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000378:metabolism*; D008297:Male; D019158:N-Acetylneuraminic Acid / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014238:Trichloroacetic Acid / Q000633:toxicity*; D000509:alpha-Fetoproteins / Q000378:metabolism
D002273:Carcinogens; D006025:Glycosaminoglycans; D000509:alpha-Fetoproteins; D014238:Trichloroacetic Acid; D002402:Cathepsin D; D019158:N-Acetylneuraminic Acid; D005944:Glucosamine; D006909:Hydroxyproline
J Gen Physiol. 1938 Sep 20;22(1):79-89
19873094
Mol Cells. 2006 Apr 30;21(2):224-8
16682817
Arch Biochem Biophys. 1961 May;93:440-7
13786180
J Clin Invest. 2001 Jul;108(2):169-73
11457867
Anal Biochem. 2000 Nov 1;286(1):149-55
11038285
Indian J Exp Biol. 2004 Aug;42(8):808-11
15573532
Bull Environ Contam Toxicol. 1983 Apr;30(4):394-9
6850127
Med Hypotheses. 2006;66(6):1115-20
16504415
Clin Chim Acta. 1973 Sep 28;48(1):15-8
4201034
Carcinogenesis. 1994 Oct;15(10):2255-61
7955063
Gastroenterology. 1998 Jan;114(1):139-52
9428228
Pharmazie. 2007 May;62(5):382-7
17557749
Clin Cancer Res. 2000 Feb;6(2):578-84
10690542
J Nucl Med. 1990 Oct;31(10):1654-8
2213188
Lab Invest. 2007 Sep;87(9):851-7
17632542
Reprod Nutr Dev. 1981;21(2):265-77
6760290
C R Acad Hebd Seances Acad Sci D. 1978 May 22;286(20):1483-5
27317
Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):571-7
15618547
Carcinogenesis. 1995 Mar;16(3):495-500
7697804
Toxicol Appl Pharmacol. 1987 Apr;88(2):225-33
3564041
Prog Drug Res. 2000;55:81-103
11127967
J Cell Sci. 1967 Dec;2(4):499-512
4169931
Environ Health Perspect. 1986 Nov;69:73-9
2880713
J Biol Chem. 1950 May;184(1):299-306
15421999
J Biol Chem. 1975 Aug 10;250(15):6151-9
125282
Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1190-6
18565195
Nat Med. 1999 Jul;5(7):793-802
10395325
Clin Chim Acta. 2003 Jan;327(1-2):139-47
12482629
Neoplasia. 2006 Apr;8(4):312-8
16756723
Biochem J. 1967 Jan;102(1):367-72
6030295
J Pharm Pharmacol. 1996 Apr;48(4):437-40
8794998
Annu Rev Cell Biol. 1993;9:541-73
8280471
Semin Cancer Biol. 2002 Jun;12(3):243-57
12083854
Cancer Res. 2005 Jul 15;65(14):6245-54
16024626
Nat Med. 1999 Jul;5(7):803-9
10395326
Z Naturforsch C J Biosci. 2004 Nov-Dec;59(11-12):897-900
15666553
Exp Toxicol Pathol. 1997 Dec;49(5):369-73
9455684
Curr Opin Chem Biol. 2000 Dec;4(6):626-31
11102866
Br Poult Sci. 1993 Sep;34(4):819-24
8242418
J Biol Chem. 1957 May;226(1):497-509
13428781
Cancer Res. 1973 Mar;33(3):613-7
4120353
J Biol Chem. 1959 Aug;234(8):1971-5
13672998
Cancer. 2000 Dec 1;89(11):2282-91
11147599
Poult Sci. 2002 Jan;81(1):92-4
11885906
Diabetologia. 1988 Feb;31(2):119-22
3282952
J Zhejiang Univ Sci B. 2006 Aug;7(8):608-14
16845712
Biochem J. 1933;27(6):1824-8
16745305
Acta Pharmacol Sin. 2007 Sep;28(9):1331-42
17723167
Anal Biochem. 1979 Oct 15;99(1):183-8
532958
Cancer. 1992 Jul 1;70(1):45-9
1318778
Mol Cancer Res. 2007 Jan;5(1):21-33
17259344
Toxicol Lett. 1995 Oct;80(1-3):97-104
7482597
Cell Signal. 1998 Jan;10(1):1-11
9502112
Arch Environ Contam Toxicol. 1988 Jul;17(4):429-36
3408265
Hepatology. 2005 Apr;41(4):857-67
15726641
World J Gastroenterol. 2005 Oct 28;11(40):6269-76
16419154
Toxicol Appl Pharmacol. 1985 Jul;79(3):365-76
4035684
Cancer Chemother Pharmacol. 1985;15(1):26-30
4006046
J Toxicol Environ Health A. 2008;71(16):1056-68
18569617
Toxicol Sci. 2000 Apr;54(2):399-407
10774822
Eur Surg Res. 2007;39(3):136-40
17337890
FASEB J. 1995 Nov;9(14):1401-10
7589981
Toxicology. 1990 Oct;64(1):71-80
2219134
J Ayub Med Coll Abbottabad. 2005 Jul-Sep;17(3):54-7
16320799
J Biol Chem. 1951 Nov;193(1):265-75
14907713